Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa

Undersea Hyperb Med. 1999 Spring;26(1):21-5.

Abstract

About 80% of nosocomial infections are caused by aerobic bacteria. Pseudomonas aeruginosa is a Gram-negative bacterium belonging to the Pseudomonadaceae family; P. aeruginosa is responsible for 6-22% of all hospital infections. The aim of this study was to evaluate the efficacy of hyperbaric oxygen (HBO2) therapy (2 atm abs x 55 min.day-1) alone for 8 days and combined with antibiotic chemotherapy (amikacin 15 mg.kg-1.day-1 for 8 days by intraperitoneal route) in rats infected subcutaneously and via the pulmonary route. In the rats infected by P. aeruginosa, HBO2 induced a reduction in mortality and morbidity with bacteria eradication in blood culture, bronchial aspirate, and skin biopsies when compared to control. These effects were increased by the use of amikacin, an antibiotic used for the treatment of sensitive Gram-negative bacteria.

MeSH terms

  • Amikacin / therapeutic use
  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Combined Modality Therapy
  • Hyperbaric Oxygenation*
  • Lung Diseases / drug therapy
  • Lung Diseases / microbiology
  • Lung Diseases / therapy*
  • Male
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / therapy*
  • Pseudomonas aeruginosa
  • Rats
  • Rats, Wistar
  • Skin Diseases, Bacterial / drug therapy
  • Skin Diseases, Bacterial / microbiology
  • Skin Diseases, Bacterial / therapy*

Substances

  • Anti-Bacterial Agents
  • Amikacin